ACE and esophageal cancer: Likewise, high daily doses of ACE inhibitors significantly reduced the risk of overall esophageal cancer (adenocarcinoma as well as squamous-cell cancer of the esophagus) by 45% (OR = 0.55; 95% CI: 0.33–0.93) in a population-based case-control study nested within the General Practitioners’ Research Database on individuals aged 40–84 years old from the UK during 1994–2001 [52].